Peer-reviewed veterinary case report
Safety and dose limits of 5-day temozolomide in dogs with cancer
By Marconato, Laura et al.·Published in Veterinary and comparative oncology·2020·Department of Veterinary Medical Sciences, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer.
- Species:
- dog
Plain-English summary
A group of dogs with advanced cancer were given a medication called temozolomide over a 5-day period to see how well they could tolerate it and what the safest dose would be. The study found that the maximum safe dose was 150 mg/m², with some dogs experiencing mild side effects like low blood platelets and liver issues, which mostly resolved on their own. No serious long-term problems were noted when some dogs received multiple doses over a longer period. This research suggests that temozolomide could be a viable treatment option for dogs with solid tumors, but more studies are needed to confirm its effectiveness.
People also search for: dog cancer treatment temozolomide · side effects of temozolomide in dogs · advanced cancer in dogs treatment options
Abstract
Temozolomide is a novel oral alkylating agent that has schedule-dependent clinical activity in human malignant glioma and metastatic melanoma. Little is known about the efficacy of temozolomide in the treatment of canine solid cancers, where broad range of dosages have been used but no maximally tolerated dose (MTD) had been established. The aim of this this open-label, dose-escalating study was to determine MTD and dose-limiting toxicity (DLT) of a single temozolomide cycle in dogs with advanced solid tumours. Temozolomide was administered as a 5-days course starting at 70 mg/m, using escalation of 10 mg/mincrements with 3 dogs per dose level. MTD was established based on the number of dogs experiencing DLT assessed after 1 cycle. Safety evaluation was performed 10 days after dosing. Thirty-three client-owned dogs were enrolled. MTD was established at 150 mg/mand the most frequent adverse events (AEs) were hematologic and hepatic, followed by gastrointestinal, with the majority being self-resolving and of mild grade. VCOG grade 3 hepatic toxicity and grade 4 thrombocytopenia were defined as DLTs at 160 mg/m. A subcohort of dogs received multiple temozolomide doses on a 4-week cycle and no cumulative toxicity was documented. Conclusions of this study define temozolomide MTD at 150 mg/mwhen given once daily over 5 days. Future trials on the efficacy of temozolomide administered at its MTD are warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32510792/